Talus Bioscience Secures $4.3M in Grants to Advance Gene Activity Drug Discovery Platform

Seattle-based biotech startup Talus Bioscience secured $4.3 million in non-dilutive grants from the Andy Hill Cancer Research Endowment and the SBIR program to advance its drug discovery platform targeting gene activity through transcription factors. The startup, led by CEO Alex Federation and CTO Lindsay Pino, has raised a total of $7 million in venture funding and $7.3 million in grants since its founding in 2020.

AAlex Federation TTalus Bio TTalus